We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential enable/disable

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name	Webedition CMS
Purpose	This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name	econda
Purpose	Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

Statistics enable/disable

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name	econda
Purpose	Statistics

External media enable/disable

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name	YouTube
Purpose	Show YouTube content
Name	Twitter
Purpose	activate Twitter Feeds

Research

INFORM2 (clinical trials)

INFORM2 (Individualized therapy For Relapsed Malignancies in childhood) translates the molecular findings of the INFORM Registry (the international next-generation diagnostics platform for progressive/relapsed malignancies) into biomarker driven phase I-II trials with new targeted/immune therapies and combinations. The first trial (INFORM2-NivEnt) is open since the end of July 2019 and further trials are in preparation, all based on new preclinical data and the availability of new (targeted) drugs. The INFORM2 trial includes trial sites in several European countries and Australia.